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Most of what we presume to understand of naturally acquired immunity to Plasmodium
falciparum malaria comes from studies in sub-Saharan Africa. The virtual absence of P.
vivax malaria from most of that region leaves three important questions not addressed: 1)
What is naturally acquired immunity to P. vivax malaria; 2) do the mechanisms of natural
immunity to P. falciparum and P. vivax malaria differ, and 3) what influence does one
species exert on acquisition of immunity to the other? Naturally acquired immunity requires
repeated and frequent exposure to infection, and few places offer sufficient exposure to both
P. falciparum and P. vivax to allow examination of these questions.
The certainty of naturally acquired immunity to P. vivax malaria derives almost entirely
from studies of neurosyphilis patients treated by repeated exposure to induced infections by
P. vivax. As with P. falciparum, a half dozen or so exposures over a relatively brief period
resulted in far lower density parasitemia and no fever. In terms of understanding naturally
acquired immunity, the neurosyphilis work has two important sources of sample bias: 1) all
subjects were adults, and 2) homologous strains of parasites were usually used. These
biases, combined with the relatively rapid onset of immunity in the clinic, ironically share
some responsibility for the long-held belief that immunity acquired by natural infections
required more than a dozen or so years of chronic, heavy exposure. The rapid onset of
immunity in neurosyphilis patients was attributed to the use of homologous strains, and the
seemingly slow onset of immunity in exposed populations was attributed to the heterologous
nature of wild strains.
This framework allowed elegant theories of susceptibility driven by antigenic polymorphism
and variability, but it also failed to answer critical questions. Do children differ inherently
from adults in their immune management of repeated infections? Do children enjoy rapid
onset of clinical immunity when challenged with homologous strains? Is onset of clinical
immunity in adults rapid with challenge by heterologous strains? These gaps in
understanding could only be addressed with studies in natural settings. In this issue of the
journal, Michon and others1 follow a cohort of school age children in holoendemic Papua
New Guinea having a remarkably high and largely equal number of exposures to P.
falciparum and P. vivax. Their work provides a rare glimpse at naturally acquired immunity
to P. vivax malaria and allows an insightful contrasting look at the same in P. falciparum
malaria.
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Their cohort of children was at equivalent risk of acquiring either P. vivax or P. falciparum
infections from the local vector populations but 21 times more likely to develop an overt
clinical response to P. falciparum than to P. vivax. The ability to regulate parasite densities
of P. vivax was also evident after nine years of age and there was no evidence of P.
falciparum density regulation throughout the school age period. The occurrence of a more
complete clinical and anti-parasitic immunity earlier in life for P. vivax compared with P.
falciparum despite comparable levels of exposure suggests different mechanisms of acquired
immunity for the two most common malaria parasites. Whether these are host-response,
individual parasite, or combined exposure related remains uncertain but merit more detailed
epidemiologic investigation. These observations buttress similar conclusions from other
studies, and emphasize the apparently strict homology of immunity within these species and
perhaps the distinct immune mechanisms at work between species.
Collins and Jeffery described essentially similar observations in neurosyphilis patients2, and
corroboration from natural settings gives weight to the experimental findings. The results
reported by Michon and others derive from an elegant field epidemiology study of infection
and disease incidence. These detailed cohort studies provide us with a wealth of information
under conditions of natural exposure and provide not only insights into the immuno-
epidmiology of infection and disease but also a reliable measure of public health burdens.
These study designs should be encouraged across a wider range of transmission settings and
dominant vector species ecologies to improve the externality of single observations.
The spatial congruence of major public health infections has led to a renewed interest in the
epidemiology and control of polyparasitic disease, including interactions and public health
outcomes associated with P. falciparum malaria and human immunodeficiency virus3,4 or P.
falciparum malaria and soil-transmitted helminths.5,6 Perhaps one of the largest and largely
ignored coincidental distributions of different parasites is the overlap between P. vivax and
P. falciparum. It has recently been estimated that 1.98 billion people are at possible risk of
both parasites worldwide.7 Now would be a good time to increase efforts to understand the
epidemiology of two of the most significant parasite species sharing the widest global reach.
Paradoxically, the neglected epidemiology and immunology of P. vivax malaria may be
effectively leveraged to more fully understand acquired immunity to P. falciparum malaria.
REFERENCES
1. Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, Susapu M, Tarongka N, Zimmerman PA,
Reeder JC, Beeson JG, Schofield L, King CL, Mueller I. The risk of malarial infections and disease
in Papua New Guinean children. Am J Trop Med Hyg. 2007; 76:997–1008. [PubMed: 17556601]
2. Collins WE, Jeffery GM. A retrospective examination of sporozoite- and trophozoite-induced
infections with Plasmodium falciparum in patients previously infected with heterologous species of
Plasmodium: effect on development of parasitologic and clinical immunity. Am J Trop Med Hyg.
1999; 61(1 Suppl):36–43. [PubMed: 10432043]
3. Korenromp EL, Williams BG, de Vlas SJ, Gouws E, Gilks CF, Ghys PD, Nahlen BL. Malaria cases
and deaths attributable to the HIV-1 epidemic in sub-Saharan Africa: a quantitative assessment at
country level. Emerg Infect Dis. 2005; 11:1410–1419. [PubMed: 16229771]
4. Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, Omoding N, Okongo M,
Malamba S, Ojwiya A. Effect of HIV-1 and increasing immuno-suppression on malaria
parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet. 2000;
356:1051–1056. [PubMed: 11009139]
5. Brooker S, Clements AC, Hotez PJ, Hay SI, Tatem AJ, Bundy DA, Snow RW. The co-distribution
of Plasmodium falciparum and hookworm among African schoolchildren. Malar J. 2006; 5:99.
[PubMed: 17083720]
6. Mwangi TW, Bethony JM, Brooker S. Malaria and helminth interactions in humans: an
epidemiological viewpoint. Ann Trop Med Parasitol. 2006; 100:551–570. [PubMed: 16989681]
BAIRD and SNOW Page 2
Am J Trop Med Hyg. Author manuscript; available in PMC 2013 March 22.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
7. Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005. Trends Parasitol.
2006; 22:353–358. [PubMed: 16798089]
BAIRD and SNOW Page 3
Am J Trop Med Hyg. Author manuscript; available in PMC 2013 March 22.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
